Madrigal Pharmaceuticals, Inc. MDGL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$309.44M+21.0% | -$288.28M+38.1% | -$289.13M+44.3% | -$281.9M+44.8% | -$391.59M+11.9% | ||
| $1.51M+15.8% | $1.51M+37.4% | $1.48M+68.8% | $1.42M+99.0% | $1.31M+129% | ||
| $111.22M+37.5% | $98.13M+22.8% | $90.02M+16.8% | $81.66M+13.7% | $80.91M+38.6% | ||
| $1.62M-13.5% | $1.6M-23.2% | $1.62M-31.4% | $1.77M-30.7% | $1.87M-29.1% | ||
| $125.93M+105% | $80.65M+49.9% | $82.82M+172% | $72.33M+948% | $61.43M— | ||
| $37.99M-30.1% | $36.98M+8.5% | $60.6M+595% | $56.43M+698% | $54.39M+6,269% | ||
| $10.41M— | $5.28M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$307.41M+31.5% | -$395.31M-1.5% | ||
| —— | —— | $1.05M-54.3% | $974K-47.7% | $1.11M-38.6% | ||
| $1.07B-8.8% | $1.05B-7.4% | $1.18B-5.7% | $1.12B+23.5% | $1.18B+63.6% | ||
| $1.14B+17.1% | $1.08B+25.5% | $1.15B+69.8% | $1.08B+87.2% | $975.37M+93.5% | ||
| —— | —— | —— | -$38.61M+90.0% | -$208.56M+22.1% | ||
| —— | —— | —— | —— | —— | ||
| $249.67M+46.9% | $255.98M-65.2% | $266.8M-77.7% | $37.61M-96.9% | $170M-84.8% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $1.62M-13.5% | $1.6M-23.2% | $1.62M-31.4% | $1.77M-30.7% | $1.87M-29.1% | ||
| $10.41M— | $5.28M— | —— | —— | —— | ||
| $5.1M+125% | $5.97M+124% | -$9.77M+28.1% | -$9.97M+26.6% | -$20.36M-300% | ||
| —— | —— | —— | —— | —— | ||
| $3.56M— | $3.21M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.14B+17.1% | $1.08B+25.5% | $1.15B+69.8% | $1.08B+87.2% | $975.37M+93.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $5.4M— | $2.6M— | ||
| —— | —— | —— | -$308.39M+31.6% | -$396.41M-1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Madrigal Pharmaceuticals, Inc. generate?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
- What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
- After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
- Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
